Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Tris Pharma Inc. is bringing back in-house a pair of attention deficit/hyperactivity disorder (ADHD) drugs - Quillivant XR and...








